Epkinly gets a second-line follicular nod
And AbbVie and Genmab scoop their ASH presentation with new data.
More delays for Regeneron
The company gets another odronextamab knockback, while a key fianlimab readout is postponed.
Regeneron shoots again with odronextamab
The company hits an FDA-mandated enrolment target, but only in follicular lymphoma.
ASH 2023 – Regeneron defends its bispecifics
Rates of infection-related deaths continue to raise eyebrows, but the company has some potential explanations.
